ES2773756R1 - Composición farmacéutica en comprimido que comprende la forma 3 de bilastina y una carga soluble en agua - Google Patents

Composición farmacéutica en comprimido que comprende la forma 3 de bilastina y una carga soluble en agua

Info

Publication number
ES2773756R1
ES2773756R1 ES201990076A ES201990076A ES2773756R1 ES 2773756 R1 ES2773756 R1 ES 2773756R1 ES 201990076 A ES201990076 A ES 201990076A ES 201990076 A ES201990076 A ES 201990076A ES 2773756 R1 ES2773756 R1 ES 2773756R1
Authority
ES
Spain
Prior art keywords
pharmaceutical composition
water soluble
soluble filler
tablet pharmaceutical
bilastine form
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
ES201990076A
Other languages
English (en)
Other versions
ES2773756A2 (es
Inventor
Chaitanya Yogananda Gujjar
Susheel Prakash Uppala
Nani Prasad Donga
Srimannarayana Bandla
Bala Ramesha Chary Rallabandi
Ruslan Staver
Hendrik Schlehahn
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alfred E Tiefenbacher GmbH and Co KG
Original Assignee
Alfred E Tiefenbacher GmbH and Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP18154203.6A external-priority patent/EP3470062B1/en
Application filed by Alfred E Tiefenbacher GmbH and Co KG filed Critical Alfred E Tiefenbacher GmbH and Co KG
Publication of ES2773756A2 publication Critical patent/ES2773756A2/es
Publication of ES2773756R1 publication Critical patent/ES2773756R1/es
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
ES201990076A 2017-12-18 2018-12-18 Composición farmacéutica en comprimido que comprende la forma 3 de bilastina y una carga soluble en agua Withdrawn ES2773756R1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IN201711045443 2017-12-18
EP18154203.6A EP3470062B1 (en) 2017-12-18 2018-01-30 Pharmaceutical tablet composition comprising bilastine polymorphic form 3 and magnesium aluminometasilicate
IN201811041577 2018-11-02
PCT/EP2018/085448 WO2019097091A1 (en) 2017-12-18 2018-12-18 Pharmaceutical tablet composition comprising bilastine form 3 and a water-soluble filler

Publications (2)

Publication Number Publication Date
ES2773756A2 ES2773756A2 (es) 2020-07-14
ES2773756R1 true ES2773756R1 (es) 2021-04-12

Family

ID=66539417

Family Applications (2)

Application Number Title Priority Date Filing Date
ES18827035T Active ES2864176T3 (es) 2017-12-18 2018-12-18 Composición farmacéutica en comprimido que comprende la forma 3 de bilastina y una carga soluble en agua
ES201990076A Withdrawn ES2773756R1 (es) 2017-12-18 2018-12-18 Composición farmacéutica en comprimido que comprende la forma 3 de bilastina y una carga soluble en agua

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES18827035T Active ES2864176T3 (es) 2017-12-18 2018-12-18 Composición farmacéutica en comprimido que comprende la forma 3 de bilastina y una carga soluble en agua

Country Status (4)

Country Link
EP (1) EP3641735B1 (es)
ES (2) ES2864176T3 (es)
PL (1) PL3641735T3 (es)
WO (1) WO2019097091A1 (es)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1505066A1 (en) * 2002-04-19 2005-02-09 Faes Farma, S.A. Polymorph of acid 4-[2-[4-[1-(2-ethoxyethyl)-1h-benzimidazole-2-il]-1-piperidinyl]ethyl]-alpha, alpha-dimethyl-benzeneacetic
WO2017017301A1 (es) * 2015-07-24 2017-02-02 Urquima, S.A Formas cristalinas de bilastina y procedimientos para su preparación
CN106692090A (zh) * 2017-02-14 2017-05-24 万全万特制药（厦门）有限公司 比拉斯汀片及其制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2124167B1 (es) 1996-06-04 1999-09-16 Espanola Prod Quimicos Nuevos derivados del bencimidazol con actividad antihistaminica.
CZ307500B6 (cs) 2012-08-15 2018-10-24 Zentiva, K.S. Způsob přípravy derivátu 2-methyl-2´-fenylpropionové kyseliny využívající nové intermediáty
SK7066Y1 (sk) 2014-01-29 2015-03-03 Zentiva Ks Kryštalický dihydrát bilastínu
CN104398481A (zh) 2014-10-29 2015-03-11 万全万特制药江苏有限公司 比拉斯汀口崩片及其制备方法
WO2017167949A1 (en) 2016-04-01 2017-10-05 Krka, D.D., Novo Mesto Crystalline forms of bilastine

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1505066A1 (en) * 2002-04-19 2005-02-09 Faes Farma, S.A. Polymorph of acid 4-[2-[4-[1-(2-ethoxyethyl)-1h-benzimidazole-2-il]-1-piperidinyl]ethyl]-alpha, alpha-dimethyl-benzeneacetic
WO2017017301A1 (es) * 2015-07-24 2017-02-02 Urquima, S.A Formas cristalinas de bilastina y procedimientos para su preparación
CN106692090A (zh) * 2017-02-14 2017-05-24 万全万特制药（厦门）有限公司 比拉斯汀片及其制备方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Neusilin® The Extraordinary Excipient for Oral Solid Dosage Forms; . [en línea][recuperado el 27.04.2017]. Recuperado de Internet (URL:https://www.fujichemical.co.jp/english/newsletter/newsletter_pharma_0711.html), *

Also Published As

Publication number Publication date
EP3641735B1 (en) 2021-02-24
ES2864176T3 (es) 2021-10-13
PL3641735T3 (pl) 2021-09-06
WO2019097091A1 (en) 2019-05-23
EP3641735A1 (en) 2020-04-29
ES2773756A2 (es) 2020-07-14

Similar Documents

Publication Publication Date Title
FIC20230005I1 (fi) Tirtsepatidi ja sen farmaseuttisesti hyväksyttävät suolat
ECSP17084331A (es) Formulaciones farmacéuticas
ITUB20159380A1 (it) Dispositivo di rilevamento pressione dotato di una cavita' e relativi metodi
DK3709978T3 (da) Farmaceutisk oral formulering omfattende bakterier
MA44720A (fr) Comprimés à désintégration orale
DK3634377T3 (da) Farmaceutisk formulering
IL273704A (en) Pharmaceutical bilayer tablet formulations
MA49837A (fr) Compositions pharmaceutiques
ZA201905763B (en) Liposomal compositions and solid oral dosage forms comprising the same
CL2016002792A1 (es) Composición en forma de una emulsión aceite en agua que comprende semilla de mostaza blanca o amarilla molida
HK1250147A1 (zh) 一種凍干藥物製劑及其用途
DK3601277T3 (da) Farmaceutisk formulering
PL2988735T3 (pl) Kompozycja farmaceutyczna zawierająca inhibitor wychwytu zwrotnego o podwójnym działaniu i sposób jego wytwarzania
PT3097907T (pt) Formulação de gel que compreende agentes analgésicos e anestésicos
ES2773756R1 (es) Composición farmacéutica en comprimido que comprende la forma 3 de bilastina y una carga soluble en agua
PT3632436T (pt) Composição farmacêutica compreendendo sais de lenvatinib
SI3236950T1 (sl) Farmacevtski sestavek, ki obsega kandesartan ali njegove farmacevtsko sprejemljive soli ali estre in amlodipin ali njegove farmacevtsko sprejemljive soli
MA49625A (fr) Compositions pharmaceutiques
AP2017009706A0 (en) Pharmaceutical compound comprising 13 glycerides, formulation and application thereof
SG11202100181YA (en) Pharmaceutical composition in the form of a chewable tablet of diosmin or a flavonoid fraction
ZA201804275B (en) Oral pharmaceutical composition comprising taste-masked n-acetylcysteine
ES1225220Y (es) Dispensador de medicamentos en tableta
UY4585S (es) Comprimidos farmacéuticos
KR102377725B1 (ko) 구조화된 구강분산성 필름
UA34521S (uk) Упаковка для лікарського засобу «урофосцин»

Legal Events

Date Code Title Description
BA2A Patent application published

Ref document number: 2773756

Country of ref document: ES

Kind code of ref document: A2

Effective date: 20200714

EC2A Search report published

Ref document number: 2773756

Country of ref document: ES

Kind code of ref document: R1

Effective date: 20210405

FA2A Application withdrawn

Effective date: 20210727